Mainz Biomed B.V. (NASDAQ:MYNZ) Now Covered by Analysts at HC Wainwright – Defense World

Research analysts at HC Wainwright initiated coverage on shares of Mainz Biomed B.V. (NASDAQ:MYNZ Get Rating) in a research report issued on Tuesday, The Fly reports. The firm set a buy rating on the stock.

MYNZ stock opened at $8.98 on Tuesday. Mainz Biomed B.V. has a 1 year low of $7.80 and a 1 year high of $30.00. The business has a 50 day simple moving average of $11.89 and a 200-day simple moving average of $13.34.

An institutional investor recently bought a new position in Mainz Biomed B.V. stock. Citadel Advisors LLC bought a new stake in Mainz Biomed B.V. (NASDAQ:MYNZ Get Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,593 shares of the companys stock, valued at approximately $120,000.

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests.

Further Reading

Receive News & Ratings for Mainz Biomed B.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed B.V. and related companies with MarketBeat.com's FREE daily email newsletter.

See the article here:
Mainz Biomed B.V. (NASDAQ:MYNZ) Now Covered by Analysts at HC Wainwright - Defense World